← Back to Screener
BioCardia, Inc. Common Stock (BCDA)
Price$1.19
Favorite Metrics
Price vs S&P 500 (26W)-20.18%
Price vs S&P 500 (4W)-9.07%
Market Capitalization$13.02M
All Metrics
Book Value / Share (Quarterly)$0.08
P/TBV (Annual)51.82x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-61.55%
Cash Flow / Share (Quarterly)$-0.69
Price vs S&P 500 (YTD)-7.44%
Gross Margin (TTM)100.00%
Net Profit Margin (TTM)-1985.85%
EPS (TTM)$-1.18
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$-1.18
Revenue Growth (5Y)-39.41%
EPS (Annual)$-1.23
ROI (Annual)-919.33%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-5649.05%
Cash / Share (Quarterly)$0.23
ROA (Last FY)-241.08%
EBITD / Share (TTM)$-0.99
ROE (5Y Avg)-462.40%
Operating Margin (TTM)-1997.45%
Cash Flow / Share (Annual)$-0.69
P/B Ratio14.55x
P/B Ratio (Quarterly)14.82x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)24.42x
Net Interest Coverage (TTM)-2.48x
ROA (TTM)-263.89%
EV / EBITDA (TTM)4.48x
EPS Incl Extra (Annual)$-1.23
Current Ratio (Annual)1.12x
Quick Ratio (Quarterly)1.03x
3-Month Avg Trading Volume0.07M
52-Week Price Return-39.90%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.75
P/S Ratio (Annual)224.47x
Asset Turnover (Annual)0.02x
52-Week High$3.20
Operating Margin (5Y Avg)-5673.79%
EPS Excl Extra (Annual)$-1.23
CapEx CAGR (5Y)-25.25%
Tangible BV CAGR (5Y)-15.15%
26-Week Price Return-16.20%
Quick Ratio (Annual)1.03x
13-Week Price Return-16.20%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.12x
Enterprise Value$10.523
Revenue / Share Growth (5Y)-30.04%
Asset Turnover (TTM)0.14x
Book Value / Share Growth (5Y)-24.84%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)5.14x
Pretax Margin (Annual)-13700.00%
Cash / Share (Annual)$0.23
3-Month Return Std Dev53.94%
Gross Margin (5Y Avg)43.27%
Net Income / Employee (TTM)$-0
ROE (Last FY)-919.33%
Net Interest Coverage (Annual)-93.75x
EPS Basic Excl Extra (Annual)$-1.23
P/FCF (TTM)39.45x
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.18
Receivables Turnover (Annual)0.00x
ROI (TTM)-221.68%
P/S Ratio (TTM)30.21x
Pretax Margin (5Y Avg)-5649.05%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.03
Price vs S&P 500 (52W)-69.73%
Year-to-Date Return-4.80%
5-Day Price Return1.71%
EPS Normalized (Annual)$-1.23
ROA (5Y Avg)-208.75%
Net Profit Margin (Annual)-13700.00%
Month-to-Date Return-1.65%
Cash Flow / Share (TTM)$-0.62
EBITD / Share (Annual)$-1.23
Operating Margin (Annual)-13794.83%
ROI (5Y Avg)-462.40%
LT Debt / Equity (Quarterly)0.06x
EPS Basic Excl Extra (TTM)$-1.18
P/TBV (Quarterly)24.70x
P/B Ratio (Annual)14.82x
Inventory Turnover (TTM)12.00x
Pretax Margin (TTM)-1985.85%
Book Value / Share (Annual)$0.08
Price vs S&P 500 (13W)-16.88%
Beta0.61x
P/FCF (Annual)39.45x
Revenue / Share (TTM)$0.00
ROE (TTM)-221.68%
52-Week Low$1.00
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
BCDABioCardia, Inc. Common Stock | 30.21x | — | 100.00% | — | $1.19 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
BioCardia is a clinical-stage company developing cell-based therapeutics for cardiovascular and pulmonary diseases with unmet medical needs. Its CardiAMP platform delivers autologous mononuclear cells derived from bone marrow to treat ischemic heart failure with reduced ejection fraction and refractory angina, while its CardiALLO platform uses off-the-shelf allogeneic mesenchymal stem cells for ischemic heart failure and acute respiratory distress syndrome. CardiALLO is currently enrolling patients in clinical trials.